Bank Hapoalim BM Sells 42,710 Shares of Pfizer Inc. $PFE

Bank Hapoalim BM decreased its position in Pfizer Inc. (NYSE:PFE) by 38.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 68,545 shares of the biopharmaceutical company’s stock after selling 42,710 shares during the quarter. Bank Hapoalim BM’s holdings in Pfizer were worth $1,747,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Aviance Capital Partners LLC lifted its position in Pfizer by 41.6% during the 3rd quarter. Aviance Capital Partners LLC now owns 139,611 shares of the biopharmaceutical company’s stock valued at $3,557,000 after acquiring an additional 41,035 shares during the period. Lmcg Investments LLC lifted its holdings in shares of Pfizer by 6.8% during the third quarter. Lmcg Investments LLC now owns 66,860 shares of the biopharmaceutical company’s stock valued at $1,704,000 after purchasing an additional 4,263 shares during the last quarter. Maryland State Retirement & Pension System lifted its holdings in shares of Pfizer by 2.6% during the third quarter. Maryland State Retirement & Pension System now owns 283,392 shares of the biopharmaceutical company’s stock valued at $7,221,000 after purchasing an additional 7,267 shares during the last quarter. Occidental Asset Management LLC purchased a new stake in shares of Pfizer in the 3rd quarter worth approximately $286,000. Finally, Gold Investment Management Ltd. increased its position in Pfizer by 2.1% during the 3rd quarter. Gold Investment Management Ltd. now owns 53,998 shares of the biopharmaceutical company’s stock valued at $1,376,000 after buying an additional 1,117 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on PFE. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. Cowen reiterated a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. Bank of America cut their price objective on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. Citigroup initiated coverage on shares of Pfizer in a report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 target price for the company. Finally, Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus target price of $27.88.

Pfizer Stock Performance

Shares of NYSE PFE opened at $25.68 on Friday. The stock has a market cap of $146.01 billion, a PE ratio of 14.93 and a beta of 0.47. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69. The firm has a fifty day moving average price of $25.35 and a 200-day moving average price of $24.99. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. The business had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.7%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is presently 100.00%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.